Tesofensine

Tesofensine was originally developed by NeuroSearch in the early 2000s and later licensed to Saniona. It was initially investigated for the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's. What it is: Tesofensine is a monoamine reuptake inhibitor that indirectly functions like a peptide modulator. It is classified as an investigational metabolic and adipolytic compound with strong appetite-suppressive qualities. Proposed Mechanisms & Research Findings: It works by inhibiting the reuptake of dopamine, serotonin, and noradrenaline in the brain. This increases synaptic concentrations of these neurotransmitters, modulating hypothalamic feeding centers to decrease food intake and increase energy expenditure. Regulatory & Safety Status: It is not FDA approved and remains in clinical trial phases. Successful Phase II trials (TIPO-1) demonstrated significant weight loss, but it is still undergoing regulatory review. Sourcing gray-market forms carries substantial psychological and cardiovascular risks. Athletic & Anti-Doping Status: It is not currently on the WADA prohibited list, but it is monitored due to its stimulant-like activity on the central nervous system.